← All trials
NCT06117306
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2024
- Primary completion
- Jan 1, 2026
- Completion date
- Jan 1, 2026
- First posted
- Nov 7, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Healing BreakthroughLead sponsor
- MAPS Public Benefit CorporationCollaborator
- National Center for PTSDCollaborator
- Department of Veteran AffairsCollaborator
- Department of Veteran AffairsReponsible party - principal investigator
- Department of Veteran AffairsCollaborator
- Department of Veteran AffairsSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.